低分子右旋糖酐扩容治疗急性脑梗死的有效性及安全性

Efficacy and safety of atorvastatin plus low-molecular-weight dextran volume expansion in the treatment of acute cerebral infarction

目的探究低分子右旋糖酐扩容治疗急性脑梗死的有效性及安全性。方法选取江苏省常州市武进中医医院2018年2月至2022年2月收治的160例急性脑梗死患者,按照随机数字表法将其分为研究组和对照组,各80例。对照组予以常规治疗+阿托伐他汀钙治疗,研究组予以低分子右旋糖酐扩容治疗。两组均治疗1周后评估疗效,比较两组血清白细胞介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)水平,比较两组日常生活能力量表(ADL)、Barthel指数(BI)、认知功能蒙特利尔认知评估法(MOCA)评分及两组不良反应发生情况。结果研究组临床疗效优于对照组,差异有统计学意义(P<0.05)。治疗1周后,两组TNF-α、IL-6、水平均低于治疗前,且研究组低于对照组,差异有统计学意义(P<0.05)。治疗1周后,两组MOCA、ADL、BI评分均高于治疗前,且研究组高于对照组,差异有统计学意义(P<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论低分子右旋糖酐扩容治疗急性脑梗死,有助于促进患者快速康复,降低炎症水平,改善认知功能,提高生活质量,安全可靠。

Objective To investigate the efficacy and safety of atorvastatin plus low-molecular-weight dextran volume expansion in the treatment of acute cerebral infarction.Methods A total of 160 cases of acute cerebral infarction admitted to Wujin Hospital of Traditional Chinese Medicine in Changzhou from February 2018 to February 2022 were selected and they were divided into study group and control group by random number table method,with 80 cases in each group.The control group received routine treatment and Atorvastatin Calcium treatment,while the study group received low-molecular-weight dextran volume expansion treatment.After one week of treatment,patients of both groups were evaluated for efficacy,serum interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)were compared between the two groups,and activities of daily life(ADL),Barthel index(BI),and Montreal cognitive assessment(MOCA)scores of cognitive function were compared between the two groups.Results The clinical efficacy of the study group was better than that of the control group,and the difference was statistically significant(P<0.05).After one week of treatment,the levels of TNF-αand IL-6 in two groups were lower than those before treatment,and the study group was lower than control group,the differences were statistically significant(P<0.05).After one week of treatment,MOCA,ADL,and BI scores in two groups were higher than those before treatment,and the study group was higher than control group,the differences were statistically significant(P<0.05).There was no significant difference in the total incidence of adverse reactions between two groups(P>0.05).Conclusion The intensive treatment of low-molecular-weight dextran volume expansion for acute cerebral infarction is helpful to promote the rapid recovery of patients,reduce the level of inflammation,improve cognitive function,improve the quality of life,and reduce the incidence of adverse reactions.